Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 12/20 | 0.78 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20774921 | 0.90 | PIK3C3 (0.80) | PIK3C3AAK1CYP3A4 | |
| SCHEMBL26612404 | 0.89 | PIK3C3 (0.79) | PIK3C3 | |
| SCHEMBL22408453 | 0.87 | PIK3C3 (1.00) | PIK3C3AAK1CYP3A4 | |
| SCHEMBL29635307 | 0.87 | PIK3C3 (1.00) | PIK3C3AAK1CYP3A4 | |
| SCHEMBL20764797 | 0.87 | PIK3C3 (0.60) | PIK3C3AAK1CYP3A4 | |
| SCHEMBL29701309 | 0.87 | PIK3C3 (0.60) | PIK3C3AAK1CYP3A4 | |
| SCHEMBL20774910 | 0.85 | PIK3C3 (0.61) | PIK3C3AAK1CYP3A4 | |
| SCHEMBL20764777 | 0.84 | PIK3C3 (1.00) | PIK3C3 | |
| SCHEMBL29035847 | 0.82 | PIK3C3 (0.71) | PIK3C3CYP3A4 | |
| SCHEMBL20765374 | 0.80 | PIK3C3 (0.77) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | claimed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117083064-A | Pyridinylpyridone derivatives as VPS34 inhibitors for the treatment of viral infections | 德西费拉制药有限责任公司 | 2023-11-17 | — | — | CN | claimed |
| US-11801238-B2 | Anti-viral activity of VPS34 inhibitors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-10-31 | — | — | US | claimed |
| EP-4251152-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | Deciphera Pharmaceuticals, LLC (US) | 2023-10-04 | — | — | EP | claimed |
| CN-111094244-B | Pyridinylpyridinone compounds | 思普瑞特生物科学公司 | 2023-07-11 | — | — | CN | claimed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | claimed |
| EP-4056556-A1 | PYRIDYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-09-14 | — | — | EP | claimed |
| US-20220218688-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-07-14 | — | — | US | claimed |
| US-20220184050-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2022-06-16 | — | — | US | claimed |
| WO-2022115545-A1 | PYRIDYLPYRIDONE DERIVATIVES AS VSP34 INHIBITORS FOR USE IN THE TREATMENT OF A VIRAL INFECTION | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | claimed |
| EP-3672941-B1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2022-02-09 | — | — | EP | claimed |
| US-11219618-B2 | Pyridylpyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2022-01-11 | — | — | US | claimed |
| US-20200289496-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2020-09-17 | — | — | US | claimed |
| EP-3672941-A1 | PYRIDYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | claimed |
| CN-111094244-A | Pyridylpyridone compounds | 思普瑞特生物科学公司 | 2020-05-01 | — | — | CN | claimed |
| WO-2019038387-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | claimed |
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | disclosed |
| WO-2019038387-A1 | PYRIDYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | STING1, TBK1, VPS4B | PIK3C3 1649/4885AAK1 826/4885CYP3A4 4483/4885 |
| US-11801238-B2 | Anti-viral activity of VPS34 inhibitors | SARS1, VPS26B, VPS4B | PIK3C3 1967/4885AAK1 1384/4885CYP3A4 3161/4885 |
| US-20220184050-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | SARS1, VPS26B, VPS4B | PIK3C3 1967/4885AAK1 1384/4885CYP3A4 3161/4885 |
| US-11219618-B2 | Pyridylpyridone compounds | PDXK, PLPBP, PNPO | PIK3C3 3788/4885AAK1 1239/4885CYP3A4 573/4885 |
| US-20200289496-A1 | PYRIDYLPYRIDONE COMPOUNDS | PDXK, PLPBP, PNPO | PIK3C3 3788/4885AAK1 1239/4885CYP3A4 573/4885 |
| US-20220218688-A1 | PYRIDYLPYRIDONE COMPOUNDS | PDXK, PLPBP, PNPO | PIK3C3 3788/4885AAK1 1239/4885CYP3A4 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.